Galmed Pharmaceuticals Ltd. filings document the company’s foreign private issuer reporting, Aramchol development disclosures and public-company governance matters. Recent Form 6-K reports furnish press releases on Aramchol-based collaborations, brain-penetrating formulation work, scientific presentations, Nasdaq minimum bid price correspondence and shareholder meeting materials.
The filing record also includes proxy and voting materials for special general meetings, incorporation of selected 6-K disclosures into Form S-8 and Form F-3 registration statements, and references to the company’s ordinary shares. These documents describe governance procedures, capital-market registration matters, listing-status communications and development updates for Galmed’s clinical-stage biopharmaceutical business.
Galmed Pharmaceuticals Ltd. approved a 1-for-8 reverse share split of its ordinary shares, consolidating every eight shares of par value NIS 1.80 into one share of par value NIS 14.40. Trading on the Nasdaq Capital Market on a post-split basis will begin on August 19, 2026.
Following the split, authorized share capital will consist of 112,500,000 ordinary shares with par value NIS 14.40 each, and issued and outstanding shares will change from 8,332,518 to approximately 1,041,565, subject to fractional treatment. Fractional shares will be rounded to the nearest whole share, and outstanding warrants and options will be adjusted proportionately.
Galmed Pharmaceuticals Ltd. reports that Nasdaq has granted an additional 180 calendar days, until January 25, 2027, for the company to regain compliance with Nasdaq’s minimum $1 bid price per share requirement.
Galmed was first notified on January 29, 2026 that its ordinary shares had traded below $1 for 30 consecutive trading days and did not regain compliance by the initial July 28, 2026 deadline. The company requested and received the extended period. Compliance will be restored if the bid price closes at or above $1 per share for at least 10 consecutive trading days before January 25, 2027. This report is incorporated by reference into Galmed’s existing Form S-8 and Form F-3 registration statements.
Galmed Pharmaceuticals Ltd., through its wholly owned subsidiary Galmed Research and Development Ltd., and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. entered into a mutual termination letter to end their 2021 License Agreement, effective July 31, 2026.
Upon termination, all rights to the licensed technology revert to Yissum, the subsidiary’s obligation to fund ongoing patent expenses ceases as of July 31, 2026, and Galmed will discontinue all activities related to the licensed technology. The company took this step to consolidate operations, reduce costs, and focus resources on commercialization of Colospan and continued development of Aramchol.
Galmed Pharmaceuticals reported progress in developing a new orally dispersible film (ODF), brain-penetrating formulation of its SCD1 inhibitor Aramchol for potential treatment of Parkinson’s disease. In preclinical work, this ODF delivery showed approximately 150% higher systemic bioavailability and about a 300% increase in CNS exposure compared with conventional oral administration.
The company highlights that up to 80% of Parkinson’s patients develop dysphagia, making standard tablets and liquids harder to use. Aramchol’s rapidly dissolving ODF formulation is designed to melt within seconds without water, aiming to ease administration and support long-term adherence. Galmed positions Aramchol ODF as a disease-modifying, mechanism-based approach targeting SCD1-linked α-synuclein aggregation, with co-development or out-licensing opportunities in a $6+ billion global Parkinson’s therapeutics market.
Galmed Pharmaceuticals Ltd. is convening its Annual General Meeting on August 26, 2026 in Ramat Gan, Israel, with a record date of July 27, 2026 and 8,262,953 Ordinary Shares outstanding, each carrying one vote. Shareholders will vote on re-electing two Class III directors until 2029, amending the articles to eliminate par value and change the company’s name to Eocene Ltd., and approving an updated compensation policy for executives and directors that raises the CEO’s potential annual and special bonuses to 275% of base salary, adjusts vesting terms, expands change-of-control benefits, and increases D&O insurance limits to $50 million. Another proposal would increase annual director fees by 20%, from $40,000 to $48,000 (and from $50,000 to $60,000 for an expert external director), citing NIS appreciation of 24.4% and 5.92% cumulative inflation. Shareholders will also vote on reappointing Brightman Almagor Zohar & Co. (Deloitte member firm) as auditor after $185k in 2025 audit fees. Most items require a simple majority, while the articles amendment needs a 75% vote and compensation items require a Special Majority.
Galmed Pharmaceuticals, a clinical-stage biopharma company, announced what it describes as a breakthrough lipid nanoparticle (LNP) formulation of its SCD1 inhibitor Aramchol that selectively targets heart tissue. Developed with Barcode Nanotech using an in vivo and AI-enabled screening platform, the new formulation is designed to redirect Aramchol’s biodistribution away from the liver toward the heart muscle.
Cardiac fibrosis, a key driver of chronic heart failure and associated with an estimated 20.5 million deaths in 2025, currently lacks therapies that directly prevent or reverse fibrosis. Aramchol has shown anti‑fibrotic activity in a Phase 3 MASH study, human heart organoids, and in‑vivo lung and heart models, and Galmed views cardiac‑targeted LNP delivery as a potential route to disease‑modifying treatments. The company also reiterates its near‑term focus on commercializing its CG‑100 colorectal surgery device and advancing Aramchol for GI oncology indications, while positioning the Barcode collaboration as a longer‑term cardiometabolic innovation platform. Galmed states that the first four paragraphs of this announcement are incorporated by reference into its existing S‑8 and F‑3 registration statements.
Galmed Pharmaceuticals reported a Q1 2026 net loss of $1.9M, wider than $1.1M a year earlier, as research and development spending more than doubled to $1.36M. General and administrative expenses rose slightly to $0.68M.
As of March 31, 2026, Galmed held current assets of $16.0M, including $1.6M in cash, $6.1M in short-term deposits and $7.8M in marketable debt securities. Management believes this supports operations for more than 12 months but expects substantial additional funding will be needed to advance development and potential commercialization.
Subsequent to quarter-end, Galmed completed the acquisition of Colospan for $3.3M in cash plus up to $2.0M in performance-based earnout tied to net revenue sales from July 1, 2027. The company also has a $20.0M Standby Equity Purchase Agreement and previously utilized an $8.1M at-the-market facility.
Galmed Pharmaceuticals Ltd. filed a prospectus supplement that incorporates a Form 6-K disclosing an amended share purchase agreement and the closing of its acquisition of Colospan Ltd. on June 22, 2026. The amended terms replace $2.0 million equity at closing with additional cash so that total cash consideration at closing is $3,300,000. The agreement also provides for a performance-based earnout of up to $2,000,000 tied to cumulative Net Sales Revenues recognized beginning July 1, 2027: no payments on the first $5,000,000 of cumulative sales, 7% on sales between $5,000,000 and $12,000,000, and 9% on sales above $12,000,000, with an overall cap of $2,000,000. The earnout accelerates on a qualifying sale/license of Colospan or if Galmed completes equity financings aggregating at least $17,500,000 post-closing. The supplement also states up to 7,500,000 ordinary shares are covered by the prospectus for resale by YA II PN, LTD.
Galmed Pharmaceuticals completed its acquisition of Colospan Ltd. on June 22, 2026 under revised, less dilutive financial terms. Instead of issuing $2.0 million in Galmed shares at closing, Galmed will pay an aggregate $3.3 million in cash to Colospan shareholders and SAFE investors.
The deal also includes up to $2.0 million in performance-based earnout tied to cumulative Net Sales Revenues from July 1, 2027, with 7% on sales between $5 million and $12 million and 9% above $12 million, capped at $2.0 million and subject to acceleration on certain strategic events or equity financings totaling at least $17.5 million. Preliminary purchase price allocation reflects total consideration of $5.3 million, including approximately $4.9 million of goodwill and intangible assets, and 7.5% of the cash consideration held in escrow for 12 months.
Through Colospan, Galmed gains CG-100, a CE-marked intraluminal bypass device for colorectal surgery with supporting clinical data from 97 patients across four trials, positioning Galmed as a broader GI-focused medtech and biopharmaceutical platform.
Galmed Pharmaceuticals Ltd. filed Post-Effective Amendment No. 3 to its Form F-1 registration statement (Registration No. 333-289703) to file the consent of Brightman Almagor Zohar & Co. dated June 8, 2026 relating to audited financial statements of Colospan Ltd. The underlying registration covers the resale of up to 7,500,000 ordinary shares. No new securities are being registered and proceeds treatment is for selling holders.